Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations

por Burdge, Gemma, Hardman, Alice, Carbery, Isabel, Broglio, Giacomo, Greer, Dan, Selinger, Christian P.
Publicado 2022

Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)

por Carbery, Isabel, Burdge, Gemma, Clark, Tanya, Broglio, Giacomo, Greer, Dan, Alakkari, Alaa, Selinger, Christian Philipp
Publicado 2023